Novo Nordisk layoffs, on the record
Every job cut, severance charge and restructuring Novo Nordisk reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from more than 60,000 to 69,505.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 20-F for 2023 | more than 60,000 | — |
| 20-F for 2024 | more than 75,000 | — |
| 20-F for 2025 | 69,505 | year-end |
Job cuts, severance and restructuring
Our summaryNovo Nordisk started a company-wide transformation to simplify the organization, speed up decisions, and shift resources to obesity and diabetes growth, and about 9,000 employees were let go worldwide.
Word for word“On 10 September 2025, Novo Nordisk initiated a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources towards the company’s growth opportunities in obesity and diabetes.” 20-F for 2025
Our summaryThe company said the transformation let go about 9,000 employees worldwide and was mostly finished by the end of 2025.
Word for word“As part of the transformation around 9,000 employees were let go globally.” 20-F for 2025
Novo Nordisk has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Novo Nordisk’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-02-04. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.